Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly



Status:Archived
Conditions:Skin Cancer, Endocrine
Therapuetic Areas:Endocrinology, Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:February 2011
End Date:April 2013

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY


This is a long term study to evaluate the safety, tolerability and efficacy of an Octreotide
Implant in patients that were previously treated with an Octreotide implant.


Evaluation on the long-term safety and tolerability, including local tolerability of the
implant site, of the 84-mg octreotide hydrogel implant in subjects with acromegaly who had
been successfully treated with the 84-mg octreotide hydrogel implant in the Phase III study
IP107-001.


We found this trial at
6
sites
Clinical Trial Facility
Medford, Oregon
?
mi
from
Medford, OR
Click here to add this to my saved trials
Clinical Trial Facility
Centralia, Illinois
?
mi
from
Centralia, IL
Click here to add this to my saved trials
Clinical Trial Facility
Chevy Chase, Maryland 20815
?
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Clinical Trial Facility
Denver, Colorado
?
mi
from
Denver, CO
Click here to add this to my saved trials
Clinical Trial Facility
Lima, Ohio
?
mi
from
Lima, OH
Click here to add this to my saved trials
Clinical Trial Facility
Mountlake Terrace, Washington
?
mi
from
Mountlake Terrace, WA
Click here to add this to my saved trials